Laura M. Nadeau

Dr. Laura M. Nadeau

Hematology | Oncology
3577 West 13 Mile Road, Suite 103, 
Royal Oak, MI 
On Staff At
Accepting New Patients
Offers Telehealth
27 Years of Experience
3577 West 13 Mile Road, Suite 103, 
Royal Oak, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laura Nadeau is a Hematologist and an Oncologist in Royal Oak, Michigan. Dr. Nadeau has been practicing medicine for over 27 years and is rated as an Experienced provider by MediFind in the treatment of Pernicious Anemia. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Adult Immune Thrombocytopenia, Chronic Familial Neutropenia, and Bone Marrow Aspiration. Dr. Nadeau is currently accepting new patients.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Case Western Reserve University, 1999
Residency
University Hospitals Case Medical Center
Specialties
Hematology
Oncology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
St. Vincent Charity Hospital
Hospital Affiliations
Corewell Health William Beaumont University Hospital
Corewell Health Beaumont Troy Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Hematology Oncology Consultants Division of Michigan Healthcare Professionals PC
3577 West 13 Mile Road, Suite 103, Royal Oak, MI 48073
Other Locations
Hematology Oncology Consultants
4550 Investment Drive, Suite B120, Troy, MI 48098

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Enrollment Status: Withdrawn
Publish Date: February 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
View 5 Less Clinical Trials

8 Total Publications

Case Report: Androgen receptor-positive, locoregionally advanced breast cancer in a transgender man and an update on breast cancer management in a gender-diverse patient population.
Case Report: Androgen receptor-positive, locoregionally advanced breast cancer in a transgender man and an update on breast cancer management in a gender-diverse patient population.
Journal: Frontiers in oncology
Published: June 25, 2025
Similar Doctors
Distinguished in Pernicious Anemia
Dr. Mukesh S. Shah
Hematology Oncology | Hematology | Oncology
Distinguished in Pernicious Anemia
Dr. Mukesh S. Shah
Hematology Oncology | Hematology | Oncology
1135 W University Dr, Ste 175, 
Rochester, MI 
 (6.3 miles away)
248-656-4900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mukesh Shah is a Hematologist Oncology specialist and a Hematologist in Rochester, Michigan. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Glossitis, Pernicious Anemia, Pleuropulmonary Blastoma, Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Shah is currently accepting new patients.

Advanced in Pernicious Anemia
Dr. Cortney V. Jones
Hematology Oncology | Hematology | Oncology
Advanced in Pernicious Anemia
Dr. Cortney V. Jones
Hematology Oncology | Hematology | Oncology

Vhs Physicians Of Michigan

6071 W Outer Dr, Sgh Professional Office Bl, 
Detroit, MI 
 (11.8 miles away)
313-966-3116
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Cortney Jones is a Hematologist Oncology specialist and a Hematologist in Detroit, Michigan. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Breast Cancer in Men, Laryngeal Cancer, Familial Colorectal Cancer, Congenital Antithrombin 3 Deficiency, and Embolectomy. Dr. Jones is currently accepting new patients.

Advanced in Pernicious Anemia
Dr. Sai R. Bikkina
Hematology Oncology | Hematology | Oncology
Advanced in Pernicious Anemia
Dr. Sai R. Bikkina
Hematology Oncology | Hematology | Oncology
1057 Suncrest Dr, Suite B, 
Lapeer, MI 
 (33.5 miles away)
810-667-4994
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Sai Bikkina is a Hematologist Oncology specialist and a Hematologist in Lapeer, Michigan. Dr. Bikkina is rated as a Distinguished provider by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Acute Mountain Sickness, and Paget Disease of the Breast. Dr. Bikkina is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nadeau's expertise for a condition
ConditionClose
    View All 19 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile